Research ArticleDrug Discovery and Translational Medicine
Integrated Pharmacokinetic/Pharmacodynamic Analysis for Determining the Minimal Anticipated Biological Effect Level of a Novel Anti-CD28 Receptor Antagonist BMS-931699
Zheng Yang, Haiqing Wang, Theodora W. Salcedo, Suzanne J. Suchard, Jenny H. Xie, Lumelle A. Schneeweis, Catherine A. Fleener, James D. Calore, Rong Shi, Sean X.Y. Zhang, A. David Rodrigues, Bruce D. Car, Punit H. Marathe and Steven G. Nadler
Journal of Pharmacology and Experimental Therapeutics December 2015, 355 (3) 506-515; DOI: https://doi.org/10.1124/jpet.115.227249
Zheng Yang
Department of Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization (Z.Y., H.W, A.D.R., B.D.C., and P.H.M.), Department of Exploratory Clinical and Translational Research (C.A.F., R.S., S.X.Y.Z.), Department of Protein Structures and Sciences (L.A.S.), Department of Immunology Discovery (S.J.S., J.H.X., and S.G.N.), Department of Bioanalytical Sciences (J.D.C.), Bristol-Myers Squibb Research and Development, Princeton, New Jersey; and Department of Drug Safety Evaluation (T.W.S.), Bristol-Myers Squibb Research and Development, New Brunswick, New Jersey
Haiqing Wang
Department of Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization (Z.Y., H.W, A.D.R., B.D.C., and P.H.M.), Department of Exploratory Clinical and Translational Research (C.A.F., R.S., S.X.Y.Z.), Department of Protein Structures and Sciences (L.A.S.), Department of Immunology Discovery (S.J.S., J.H.X., and S.G.N.), Department of Bioanalytical Sciences (J.D.C.), Bristol-Myers Squibb Research and Development, Princeton, New Jersey; and Department of Drug Safety Evaluation (T.W.S.), Bristol-Myers Squibb Research and Development, New Brunswick, New Jersey
Theodora W. Salcedo
Department of Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization (Z.Y., H.W, A.D.R., B.D.C., and P.H.M.), Department of Exploratory Clinical and Translational Research (C.A.F., R.S., S.X.Y.Z.), Department of Protein Structures and Sciences (L.A.S.), Department of Immunology Discovery (S.J.S., J.H.X., and S.G.N.), Department of Bioanalytical Sciences (J.D.C.), Bristol-Myers Squibb Research and Development, Princeton, New Jersey; and Department of Drug Safety Evaluation (T.W.S.), Bristol-Myers Squibb Research and Development, New Brunswick, New Jersey
Suzanne J. Suchard
Department of Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization (Z.Y., H.W, A.D.R., B.D.C., and P.H.M.), Department of Exploratory Clinical and Translational Research (C.A.F., R.S., S.X.Y.Z.), Department of Protein Structures and Sciences (L.A.S.), Department of Immunology Discovery (S.J.S., J.H.X., and S.G.N.), Department of Bioanalytical Sciences (J.D.C.), Bristol-Myers Squibb Research and Development, Princeton, New Jersey; and Department of Drug Safety Evaluation (T.W.S.), Bristol-Myers Squibb Research and Development, New Brunswick, New Jersey
Jenny H. Xie
Department of Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization (Z.Y., H.W, A.D.R., B.D.C., and P.H.M.), Department of Exploratory Clinical and Translational Research (C.A.F., R.S., S.X.Y.Z.), Department of Protein Structures and Sciences (L.A.S.), Department of Immunology Discovery (S.J.S., J.H.X., and S.G.N.), Department of Bioanalytical Sciences (J.D.C.), Bristol-Myers Squibb Research and Development, Princeton, New Jersey; and Department of Drug Safety Evaluation (T.W.S.), Bristol-Myers Squibb Research and Development, New Brunswick, New Jersey
Lumelle A. Schneeweis
Department of Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization (Z.Y., H.W, A.D.R., B.D.C., and P.H.M.), Department of Exploratory Clinical and Translational Research (C.A.F., R.S., S.X.Y.Z.), Department of Protein Structures and Sciences (L.A.S.), Department of Immunology Discovery (S.J.S., J.H.X., and S.G.N.), Department of Bioanalytical Sciences (J.D.C.), Bristol-Myers Squibb Research and Development, Princeton, New Jersey; and Department of Drug Safety Evaluation (T.W.S.), Bristol-Myers Squibb Research and Development, New Brunswick, New Jersey
Catherine A. Fleener
Department of Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization (Z.Y., H.W, A.D.R., B.D.C., and P.H.M.), Department of Exploratory Clinical and Translational Research (C.A.F., R.S., S.X.Y.Z.), Department of Protein Structures and Sciences (L.A.S.), Department of Immunology Discovery (S.J.S., J.H.X., and S.G.N.), Department of Bioanalytical Sciences (J.D.C.), Bristol-Myers Squibb Research and Development, Princeton, New Jersey; and Department of Drug Safety Evaluation (T.W.S.), Bristol-Myers Squibb Research and Development, New Brunswick, New Jersey
James D. Calore
Department of Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization (Z.Y., H.W, A.D.R., B.D.C., and P.H.M.), Department of Exploratory Clinical and Translational Research (C.A.F., R.S., S.X.Y.Z.), Department of Protein Structures and Sciences (L.A.S.), Department of Immunology Discovery (S.J.S., J.H.X., and S.G.N.), Department of Bioanalytical Sciences (J.D.C.), Bristol-Myers Squibb Research and Development, Princeton, New Jersey; and Department of Drug Safety Evaluation (T.W.S.), Bristol-Myers Squibb Research and Development, New Brunswick, New Jersey
Rong Shi
Department of Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization (Z.Y., H.W, A.D.R., B.D.C., and P.H.M.), Department of Exploratory Clinical and Translational Research (C.A.F., R.S., S.X.Y.Z.), Department of Protein Structures and Sciences (L.A.S.), Department of Immunology Discovery (S.J.S., J.H.X., and S.G.N.), Department of Bioanalytical Sciences (J.D.C.), Bristol-Myers Squibb Research and Development, Princeton, New Jersey; and Department of Drug Safety Evaluation (T.W.S.), Bristol-Myers Squibb Research and Development, New Brunswick, New Jersey
Sean X.Y. Zhang
Department of Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization (Z.Y., H.W, A.D.R., B.D.C., and P.H.M.), Department of Exploratory Clinical and Translational Research (C.A.F., R.S., S.X.Y.Z.), Department of Protein Structures and Sciences (L.A.S.), Department of Immunology Discovery (S.J.S., J.H.X., and S.G.N.), Department of Bioanalytical Sciences (J.D.C.), Bristol-Myers Squibb Research and Development, Princeton, New Jersey; and Department of Drug Safety Evaluation (T.W.S.), Bristol-Myers Squibb Research and Development, New Brunswick, New Jersey
A. David Rodrigues
Department of Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization (Z.Y., H.W, A.D.R., B.D.C., and P.H.M.), Department of Exploratory Clinical and Translational Research (C.A.F., R.S., S.X.Y.Z.), Department of Protein Structures and Sciences (L.A.S.), Department of Immunology Discovery (S.J.S., J.H.X., and S.G.N.), Department of Bioanalytical Sciences (J.D.C.), Bristol-Myers Squibb Research and Development, Princeton, New Jersey; and Department of Drug Safety Evaluation (T.W.S.), Bristol-Myers Squibb Research and Development, New Brunswick, New Jersey
Bruce D. Car
Department of Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization (Z.Y., H.W, A.D.R., B.D.C., and P.H.M.), Department of Exploratory Clinical and Translational Research (C.A.F., R.S., S.X.Y.Z.), Department of Protein Structures and Sciences (L.A.S.), Department of Immunology Discovery (S.J.S., J.H.X., and S.G.N.), Department of Bioanalytical Sciences (J.D.C.), Bristol-Myers Squibb Research and Development, Princeton, New Jersey; and Department of Drug Safety Evaluation (T.W.S.), Bristol-Myers Squibb Research and Development, New Brunswick, New Jersey
Punit H. Marathe
Department of Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization (Z.Y., H.W, A.D.R., B.D.C., and P.H.M.), Department of Exploratory Clinical and Translational Research (C.A.F., R.S., S.X.Y.Z.), Department of Protein Structures and Sciences (L.A.S.), Department of Immunology Discovery (S.J.S., J.H.X., and S.G.N.), Department of Bioanalytical Sciences (J.D.C.), Bristol-Myers Squibb Research and Development, Princeton, New Jersey; and Department of Drug Safety Evaluation (T.W.S.), Bristol-Myers Squibb Research and Development, New Brunswick, New Jersey
Steven G. Nadler
Department of Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization (Z.Y., H.W, A.D.R., B.D.C., and P.H.M.), Department of Exploratory Clinical and Translational Research (C.A.F., R.S., S.X.Y.Z.), Department of Protein Structures and Sciences (L.A.S.), Department of Immunology Discovery (S.J.S., J.H.X., and S.G.N.), Department of Bioanalytical Sciences (J.D.C.), Bristol-Myers Squibb Research and Development, Princeton, New Jersey; and Department of Drug Safety Evaluation (T.W.S.), Bristol-Myers Squibb Research and Development, New Brunswick, New Jersey
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleDrug Discovery and Translational Medicine
Integrated PK/PD Analysis for MABEL Determination
Zheng Yang, Haiqing Wang, Theodora W. Salcedo, Suzanne J. Suchard, Jenny H. Xie, Lumelle A. Schneeweis, Catherine A. Fleener, James D. Calore, Rong Shi, Sean X.Y. Zhang, A. David Rodrigues, Bruce D. Car, Punit H. Marathe and Steven G. Nadler
Journal of Pharmacology and Experimental Therapeutics December 1, 2015, 355 (3) 506-515; DOI: https://doi.org/10.1124/jpet.115.227249
Research ArticleDrug Discovery and Translational Medicine
Integrated PK/PD Analysis for MABEL Determination
Zheng Yang, Haiqing Wang, Theodora W. Salcedo, Suzanne J. Suchard, Jenny H. Xie, Lumelle A. Schneeweis, Catherine A. Fleener, James D. Calore, Rong Shi, Sean X.Y. Zhang, A. David Rodrigues, Bruce D. Car, Punit H. Marathe and Steven G. Nadler
Journal of Pharmacology and Experimental Therapeutics December 1, 2015, 355 (3) 506-515; DOI: https://doi.org/10.1124/jpet.115.227249
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement